Journal of Hypertension最新文献

Objectives: Identification of nondialysis chronic kidney disease (CKD) patients at a higher risk of end-stage kidney disease (ESKD) or adverse cardiovascular events is the first essential step to optimize management. We evaluated the role of left ventricular ejection fraction (LVEF) in predicting cardiac and renal outcome in CKD.

Methods: We prospectively studied 580 consecutive patients with nondialysis CKD followed in two Italian renal clinics in order to evaluate the association between LVEF as either continuous variable or categories (>60, 50-60 and <50%) and adjusted risks (hazard ratio, 95% confidence interval) of either cardiovascular (composite of fatal and nonfatal cardiovascular events) or renal events (composite of ESKD and all-cause death before ESKD).

Results: The mean age of participants was 65.0 ± 13.5 years, 62% men, eGFR 41.3 ± 21.1 ml/min/1.73 m 2 , LVEF 60.6 ± 8.1% and left ventricular mass index (LVMI) 59.3 ± 17.6 g/m 2.7 . LVEF more than 60%, 50-60% and <50% was recorded in 274, 234 and 72 patients, respectively. Patients with LVEF less than 50% were predominantly men with more frequent history of cardiovascular disease and lower eGFR; in addition, they had higher 24 h, daytime and nighttime blood pressure. During the follow-up (median 5.0 years, IQR 4.9-7.1), cardiovascular and renal endpoints were registered in 113 and 228 patients, respectively. LVEF as a continuous variable was inversely associated with the adjusted risk of either cardiovascular (0.97, 0.95-0.99) or renal endpoint (0.98, 0.97-0.995). In comparison with patients with LVEF more than 60%, the risk of cardiovascular events was increased in patients with LVEF 50-60% (1.64, 1.06-2.53) and less than 50% (2.17, 1.27-3.72). The same occurred for renal endpoint (1.68, 1.24-2.27 and 1.73, 1.15-2.59 for LVEF 50-60% and <50%, respectively).

Conclusion: In CKD patients, lower LVEF is associated with worse cardiorenal prognosis, independently from LVMI.

Objective: Vascular pathology, characterized by impaired vasoreactivity and mitochondrial respiration, differs between the sexes. Housing rats under thermoneutral (TN) conditions causes vascular dysfunction and perturbed metabolism. We hypothesized that thoracic perivascular adipose tissue (tPVAT), a vasoregulatory adipose depot known to have a brown adipose tissue (BAT) phenotype, remodels to a mainly white adipose (WAT) phenotype in rats housed at TN, driving diminished vasoreactivity in a sex-dependent manner.

Methods: Male and female Wistar rats were housed at either room temperature (RT) or TN. We measured changes in tPVAT morphology, vasoreactivity in vessels with intact tPVAT or transferred to tPVAT of the oppositely-housed animal, vessel stiffness, vessel mitochondrial respiration and cellular signaling.

Results: Remodeling of tPVAT was observed in rats housed at TN; animals in this environment showed tPVAT whitening and displayed diminished aortae vasodilation ( P  < 0.05), different between the sexes. Juxtaposing tPVAT from RT rats onto aortae from TN rats in females corrected vasodilation ( P  < 0.05); this did not occur in males. In aortae of all animals housed at TN, mitochondrial respiration was significantly diminished in lipid substrate experiments ( P  < 0.05), and there was significantly less expression of phosphorylated endothelial nitric oxide synthase (peNOS) ( P  < 0.001).

Conclusions: These data are consistent with TN-induced remodeling of tPVAT, notably associated with sex-specific blunting of vasoreactivity, diminished mitochondrial respiration, and altered cellular signaling.

Introduction: Normal pregnancy is associated with cardiovascular changes that enable adaptation to the pregnancy state. We sought to describe the haemodynamic changes from prepregnancy to very early pregnancy in women planning to conceive in southwestern Uganda.

Methods: In this prospective cohort study, we enrolled women in southwestern Uganda planning to conceive. Brachial and central blood pressure, heart rate, cardiac output, stroke volume, and peripheral vascular resistance were assessed prepregnancy and repeated in very early pregnancy.

Results: We studied 86 women with a mean age of 27.8 years (SD ± 4.4). The mean gestational age was 7 (±2) weeks at the time of repeat blood pressure measurement. Brachial systolic and diastolic blood pressure decreased in very early pregnancy (116 ± 11 to 114 ± 8 mmHg and 68 ± 6 to 65 ± 5 mmHg, respectively; P  < 0.001). Central systolic and diastolic blood pressure also decreased (112 ± 10 to 109 ± 8 mmHg, P  = 0.003 and 68 ± 6 to 65 ± 5 mmHg, P  < 0.001, respectively), as did peripheral vascular resistance (1450 ± 581 to 1311 ± 276 dyn/s/cm 5P  = 0.038). There was no significant difference in cardiac output (5.3 ± 1.2 vs 5.5 ± 1.1 l/min P  = 0.146) or stroke volume (64 ± 13 to 66 ± 12 ml, P  = 0.172).

Conclusion: Significant haemodynamic changes occur in very early pregnancy. Using late first trimester measurements as a baseline for pregnancy induced changes may not be suitable for understanding the full extent of pregnancy induced haemodynamic changes, or provide a reliable substitute for prepregnancy states.

Our objective was to explore the effect of aerobic exercise on endothelial function in hypertensive and prehypertensive patients, and to ascertain the optimal duration and intensity of aerobic exercise. Data were synthesized using a random effects model to calculate the weighted mean difference (WMD) and 95% confidence interval (CI). Fifteen studies met the inclusion criteria. Aerobic exercise was found to significantly improve flow-mediated dilation (FMD) in prehypertensive and hypertensive patients (WMD, 2.23; 95% CI, 1.20-3.26; P  < 0.0001; I2  = 90%). Aerobic exercise, undertaken at a moderate or, even better, vigorous intensity, and lasting no less than 12 weeks, is an effective approach to improve flow-mediated dilation (FMD) in prehypertensive and hypertensive patients. The effect of aerobic exercise on endothelial function is influenced by participant characteristics: a better health status, a younger age, a larger basal body mass index, and a larger basal FMD were associated with larger improvement in FMD.

There are inconsistencies in the effect of raising or lowering body salt on blood pressure (BP). We hypothesize that they are caused in part by differences in plasma renin activity (PRA). PRA changes reciprocally with body salt. PRA is the rate limiting step in the formation of the vasoconstrictor peptide angiotensin II (Ang II) in the circulation where it cleaves Ang I from plasma angiotensinogen, and then Ang I is rapidly converted to Ang II by angiotensin-converting enzyme in plasma and vascular endothelial cells. We hypothesize that PRA levels above 0.65 ng/ml/h lead to sufficient Ang II production to cause vasoconstriction, whereas lower levels do not. PRA is usually more than 0.65 in normotensives who are not on a high-salt diet; in them, the increase in PRA/Ang II vasoconstriction caused by reduction in body salt (low-salt diet, diuretic use) is large enough to prevent BP from falling. By contrast, a similar reduction in body salt lowers BP in the 30% of hypertensive patients with low baseline PRA (<0.65 ng/ml/h), because vasoconstriction does not increase in that range. A similar reduction in body salt also lowers BP in the 60% of hypertensive patients with baseline PRA between 0.65 and 4.5 ng/ml/h, but for a different reason; the rise in PRA and the increase in vasoconstriction is too small to prevent BP from falling. However, after body salt has been reduced enough to raise PRA above 4.5 ng/ml/h, further salt depletion increases PRA to a greater extent, and BP does not fall. Renin-angiotensin system (RAS) inhibitors leave a small amount of renin unblocked. In salt-depleted hypertensive patients, they also raise PRA enough to prevent BP from falling significantly. We propose that this PRA/Ang II vasoconstrictor effect related to reactive increases in PRA can prevent or attenuate the decrease in BP caused by excessive salt depletion, even during concurrent RAS inhibition. This phenomenon, if confirmed, could inform new strategies to optimize the treatment of hypertension, cardiovascular disease (CVD) and chronic kidney disease (CKD).

Background: Metabolic bariatric surgery (MBS) reduces the risk of new-onset hypertension; however, it is unclear whether this effect varies according to patient sex, age, or socioeconomic background. This study aimed to assess the risk of new-onset arterial hypertension after MBS, with a special focus on these patient characteristics.

Methods: This follow-up study with matched controls was nested in a large employee cohort, the Finnish Public Sector study, consisting of individuals with no hypertension at baseline. For each patient who underwent laparoscopic MBS between 2008 and 2016, two propensity-score matched controls were selected from individuals hospitalized with a diagnosis of obesity or individuals with self-reported severe obesity [body mass index (BMI) ≥ 35 kg/m 2 ] but no recorded history of MBS. Cases of new-onset hypertension were identified via linked electronic health records from the national health registries until December 31, 2016.

Results: The study included 912 patients and 1780 matched controls. The rate of new-onset hypertension per 1000 person-years was 2.8 in the surgery group and 9.6 in the control group, with a rate ratio of 0.29 (95% confidence intervals 0.15-0.57) and a rate difference of -6.8 (95% confidence intervals -9.6 to -4.0) per 1000 person-years. No significant differences in rate reduction after MBS were observed to be associated with patient sex, age, or socioeconomic status.

Conclusion: Metabolic bariatric surgery reduces the risk of new-onset arterial hypertension across all age-, sex-, and socioeconomic subgroups.

A previously healthy young man developed severe hypertension requiring triple antihypertensive therapy. Initial evaluation identified hyperreninemic hyperaldosteronism, mild hypokalaemia, hypodensity within the right kidney at computed tomography (CT), normal renal arteries at echography. He was referred to Verona ESH Centre were angio-CT revealed significant stenosis of an aberrant branch artery of the right kidney with hypo-perfused area colocalizing with a hypo-oxygenated area, as assessed by BOLD-MR imaging. Super-selective sampling found high plasma renin concentrations only in the vein draining the lower pole of the right kidney. Renal angiography confirmed tightened stenosis of an aberrant branch artery supplying the lower arterial segments, consistent with unifocal medial fibromuscular dysplasia, successfully treated with angioplasty. Investigating extra-renal sites, angio-MR found an S-shaped loop of extracranial left internal carotid artery, consistent with multisite fibromuscular dysplasia. This clinical case underscores the importance of comprehensive functional and imaging tests to identify elusive causes of secondary hypertension.

Backgroundaims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for cardiovascular morbidity and mortality. Another critical risk factor in these patients is arterial hypertension (AH). Although it is estimated that 50% of MASLD patients are suffering from AH, 24-h ambulatory blood pressure monitoring (24-h-ABPM), the gold standard for diagnosing hypertension, is often neglected. However, only 24-h-ABPM can identify hypertension subtypes, particularly nocturnal hypertension (NH), which is a stronger predictor of cardiovascular mortality than daytime or 24-h blood pressure. The aim of this study was to investigate the prevalence of NH in MASLD patients and to identify associated risk factors.

Methods: To this end, 226 MASLD patients with or without known AH were prospectively recruited in an outpatient liver department and underwent 24-h-ABPM together with repeated office-blood-pressure measurements.

Results: 24-h-ABPM datasets from 218 patients were included in the final analysis. NH was observed in 112 patients (51.3%), of whom 54 (48.2%) were receiving antihypertensive treatment (uncontrolled hypertension). Univariable regression analysis showed that age, increased waist-to-hip ratio, a waist-to-height ratio ≥0.5, type 2 diabetes mellitus (T2DM), dyslipidemia, a lower estimated glomerular filtration rate and increased liver stiffness were significantly associated with a higher risk of NH. In multivariable regression analysis, T2DM [odds ratio (OR) 2.56; 95% confidence interval (CI) 1.09-6.23; P  = 0.033], dyslipidemia (OR 3.30; 95% CI, 1.67-6.73; P  = 0.001) and liver stiffness (OR 1.09; 95% CI, 1.02-1.18; P  = 0.021) were identified as independent risk factors.

Conclusions: In conclusion, particularly MASLD patients with accompanying T2DM, dyslipidemia, and increased liver stiffness should undergo 24-h-ABPM to detect and treat NH, as they are at the highest risk of adverse cardiovascular events.

Clinical trial: NCT-04543721.

Background: Hypertension is a common public health problem characterized by high blood pressure (BP) and associated with complications such as coronary artery disease, stroke, and renal failure. Physical activity and exercise regulate BP, and assessment of exercise capacity is a cornerstone of exercise training.

Objective: The aims of this study were to evaluate the validity and reliability of the 6-min stepper test (6MST) in hypertensive individuals and compare their physiological responses during the 6MST and 6-min walk test (6MWT).

Methods: Forty individuals with hypertension were included. Participants performed the 6MWT and 6MST in separate morning and afternoon sessions. In each session, the test was repeated twice with a 30-min rest interval. Heart rate (HR), BP, perceived dyspnea, general fatigue, and leg fatigue were measured pre and posttest. Intraclass correlation coefficient (ICC), Bland-Altman plots, and standard error of measurement (SEM) were used to assess reliability. Pearson correlation analysis was used for convergent validity.

Results: There was a strong and significant correlation between 6MWT distance and 6MST score ( r  = 0.689, P  < 0.001). Physiological responses during the 6MST had ICC values ranging from 0.70 to 0.89, suggesting good to excellent test-retest reliability. The SEM and minimum detectable difference (MDD) indicated the 6MST had low measurement error and high sensitivity.

Conclusion: The 6MST is a valid and reliable tool for assessing exercise capacity in people with HTN. Its practicality and ease of use make it a suitable alternative to the 6MWT for this population.